<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2631-2581</journal-id>
<journal-title><![CDATA[Revista Ecuatoriana de Neurología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Ecuat Neurol]]></abbrev-journal-title>
<issn>2631-2581</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Médica Ecuatoriana de Neurología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2631-25812019000300059</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Perspectivas en el abordaje farmacológico de la Epilepsia: una revisión extensa de la farmacoterapia]]></article-title>
<article-title xml:lang="en"><![CDATA[Perspectives on the pharmacologic management of epilepsy: A comprehensive review]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Aguirre]]></surname>
<given-names><![CDATA[Luis E.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[De Leon-Benedetti]]></surname>
<given-names><![CDATA[Andres]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Jackson Memorial Hospital Division de Medicina Interna ]]></institution>
<addr-line><![CDATA[Miami Florida]]></addr-line>
<country>USA</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Jackson Memorial Hospital Division de Neurologia ]]></institution>
<addr-line><![CDATA[Miami Florida]]></addr-line>
<country>USA</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2019</year>
</pub-date>
<volume>28</volume>
<numero>3</numero>
<fpage>59</fpage>
<lpage>67</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.senescyt.gob.ec/scielo.php?script=sci_arttext&amp;pid=S2631-25812019000300059&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.senescyt.gob.ec/scielo.php?script=sci_abstract&amp;pid=S2631-25812019000300059&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.senescyt.gob.ec/scielo.php?script=sci_pdf&amp;pid=S2631-25812019000300059&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Antecedentes:  La epilepsia constituye la tercera causa más común de trastorno neurológico que se reporta, secundario tan solo a eventos cerebrovasculares y enfermedad de Alzheimer. Se ha determinado que aproximadamente entre el 70% al 80% de los cuadros convulsivos son controlados exitosamente con monoterapia, aproximadamente el 10-15% con terapia combinada mientras que cerca del 10% no son controlados con terapia farmacológica solamente.  Objetivo: El presente documento constituye una revisión bibliográfica que pretende exponer las alternativas en el abordaje actual de cuadros de epilepsia. No pretende hacer de guía terapéutica senso estricto, sino dotar al médico tratante de herramientas que simplifiquen la selección del fármaco apropiado de acorde a su criterio, circunstancias y realidad clínica.  Metodología: Se recurrió a motores de búsqueda médicos, artículos y resúmenes, al igual que a guías publicadas por la ILAE con el objetivo de recolectar datos pertinentes e interpretar estos hallazgos.  Conclusión: Mediante esta revisión se logró exponer criterios clásicos e innovadores abarcando la extensión del conocimiento actual respecto al abordaje farmacológico de la epilepsia.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Background: Epilepsy represents the third most common reported neurologic disorder, surpassed only by cerebrovascular accidents and Alzheimer&#8217;s disease. Iyt is believed that around 70% to 80% of all convulsive disorders can be successfully controlled with monotherapy alone and an additional 10% to 15% with combination therapy. Around 10% of cases never achieve remission through pharmacological therapy alone.  Objectives: Through this comprehensive review of the literature describing the current available pharmacologic therapies for the management of epilepsy and their recognized indications, the authors intend to provide an educational tool that could assist the general practitioner to make decisions when selecting a suitable treatment strategy according to a specific clinical scenario (and as guided by their own professional judgment, circumstances and clinical reality)-.  Methods: We used a wide variety of medical search engines, articles and abstracts for the purpose of data collection and interpretation.  Conclusions: Through this review the authors managed to present all current and innovative approaches regarding the pharmacologic management of epilepsy encompassing the scope of current knowledge.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Epilepsia]]></kwd>
<kwd lng="es"><![CDATA[Farmacoterapia]]></kwd>
<kwd lng="es"><![CDATA[Anticonvulsivantes]]></kwd>
<kwd lng="es"><![CDATA[Convulsiones.]]></kwd>
<kwd lng="en"><![CDATA[Epilepsy]]></kwd>
<kwd lng="en"><![CDATA[Pharmacotherapy]]></kwd>
<kwd lng="en"><![CDATA[Anticonvulsants]]></kwd>
<kwd lng="en"><![CDATA[Seizures.]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[HARVEY]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[CLARK]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[FINKEL]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[REY]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[WHALEN]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<source><![CDATA[Pharmacology]]></source>
<year>2012</year>
<volume>15</volume>
<edition>5th Edition</edition>
<page-range>181-92</page-range><publisher-loc><![CDATA[Lippincott ]]></publisher-loc>
<publisher-name><![CDATA[Williams & Wilkins]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Recommendations for the management of &#8220;febrile seizures&#8221;]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[CAPOVILLA]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[MASTRANGELO]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[ROMEO]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Epilepsia]]></source>
<year>2009</year>
<volume>50</volume>
<numero>^sSuppl. 1</numero>
<issue>^sSuppl. 1</issue>
<supplement>Suppl. 1</supplement>
<page-range>2-6</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A definition and classification of status epilepticus - Report of the ILAE Task Force on Classification of Status Epilepticus]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[TRUNK]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[COCK]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[HESDORFFER]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[Epilepsia]]></source>
<year>2015</year>
<volume>56</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1515-23</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="">
<collab>ILAE</collab>
<source><![CDATA[Treatment of Epilepsy (undated manuscrpit)]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[GLAUSER]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[BEN-MENACHEM]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[BOURGEOIS]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<source><![CDATA[Epilepsia]]></source>
<year>2013</year>
<page-range>1-13</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="">
<collab>Eisai Inc.</collab>
<source><![CDATA[Drug Label Information about Zonegran (Zonisamide capsules)]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="">
<collab>Food and Drugs Administration</collab>
<source><![CDATA[Information for Healthcare Professionals: Zonisamide (marketed as Zonegran, and generics).]]></source>
<year>2013</year>
</nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Antiepileptic drugs.]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[OCHOA]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[RICHIE]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<source><![CDATA[Medscape]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Seizure medication list]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[SIRVEN]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[SHAFER]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[Epilepsy foundation]]></source>
<year>2014</year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
